-
Mashup Score: 1A bi-steric mTORC1-selective inhibitor overcomes drug resistance in breast cancer - Oncogene - 11 month(s) ago
Activation of the PI3K-mTOR pathway is central to breast cancer pathogenesis including resistance to many targeted therapies. The mTOR kinase forms two distinct complexes, mTORC1 and mTORC2, and understanding which is required for the survival of malignant cells has been limited by tools to selectively and completely impair either subcomplex. To address this, we used RMC-6272, a bi-steric…
Source: NatureCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Our results show that everolimus delays mammary tumor formation in multiple mouse models, suggesting that mTOR inhibitors will be useful for the prevention of ER-negative and triple-negative breast cancer in humans.
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
From the December Issue— Targeting the #mTOR Pathway for the Prevention of ER-Negative #BreastCancer, by Mazumdar et al. https://t.co/a1J5OnjOmC @MDAndersonNews https://t.co/w5lDu1tmNR
-
-
Mashup Score: 0
Our results show that everolimus delays mammary tumor formation in multiple mouse models, suggesting that mTOR inhibitors will be useful for the prevention of ER-negative and triple-negative breast cancer in humans.
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
From the December Issue— Targeting the #mTOR Pathway for the Prevention of ER-Negative #BreastCancer, by Mazumdar et al. https://t.co/0lft6Mr8tA @MDAndersonNews https://t.co/TxBdFMlyaO
-
-
Mashup Score: 2
Abstract. The mechanistic target of rapamycin (mTOR) plays a key role in normal and malignant cell growth. However, pharmacologic targeting of mTOR in cancer has shown little clinical benefit, in spite of aberrant hyperactivation of mTOR in most solid tumors. Here, we discuss possible reasons for the reduced clinical efficacy of mTOR inhibition and highlight lessons learned from recent…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In the latest Cancer Research Controversy and Consensus article, @kcw00d and @SilvioGutkind discuss the challenges and emerging opportunities for targeting #mTOR in cancer. https://t.co/aVQKbUySBb @DukeCancer https://t.co/XesMTOvVO7
-
-
Mashup Score: 4
Abstract. The mechanistic target of rapamycin (mTOR) plays a key role in normal and malignant cell growth. However, pharmacologic targeting of mTOR in cancer has shown little clinical benefit, in spite of aberrant hyperactivation of mTOR in most solid tumors. Here, we discuss possible reasons for the reduced clinical efficacy of mTOR inhibition and highlight lessons learned from recent…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In the latest Cancer Research Controversy and Consensus article, @kcw00d and @SilvioGutkind discuss the challenges and emerging opportunities for targeting #mTOR in cancer. https://t.co/CZmd83DYq8 @DukeCancer https://t.co/tZgmwjAr5L
-
-
Mashup Score: 0Protein Tyrosine Phosphatase PTPRO Signaling Couples Metabolic States to Control the Development of Granulocyte Progenitor Cells - 2 year(s) ago
Protein tyrosine phosphatase (PTPase) is critically involved in the regulation of hematopoietic stem cell development and differentiation. Roles of novel isolated receptor PTPase PTPRO from bone marrow hematopoietic stem cells in granulopoiesis have not been investigated. PTPRO expression is
Source: The Journal of ImmunologyCategories: Allergy-Immunology, Latest HeadlinesTweet-
Previously unrecognized interplay between a #ProteinTyrosinePhosphatase and #mTOR- #HIF1α metabolic reprogramming in progenitor cells of #granulocytes, from Guangwei Lu at Beijing Normal University | #ReadTheJI #immunology #VisualAbstract https://t.co/PFQkQlIi9X https://t.co/LheYAoA4p8
-
-
Mashup Score: 7Protocol for the assessment of mTOR activity in mouse primary hepatocytes: STAR Protocols - 2 year(s) ago
Summary We present a protocol for measuring the activity of the mechanistic target of rapamycin (mTOR) pathway in ex vivo isolated mouse primary hepatocytes. It can be used as a tool for genetic, pharmacological, metabolomic, and signal transduction procedures. We discuss critical aspects for improving yield, viability, and modulation of the mTOR pathway. This protocol can…
Source: star-protocols.cell.comCategories: General Medicine News, Latest HeadlinesTweet-
Online now in @STARProtocols: Dr. Alejo Efeyan's lab @EfeyanLab @_AnaBelenAg @Gsabiolab @CNIOStopCancer for measuring the activity of #mTOR pathway in ex vivo isolated mouse primary #hepatocytes: https://t.co/6PPggUZP75 Featuring 4 method videos! https://t.co/md5D91bijs
-
-
Mashup Score: 11Current issue: Trends in Immunology - 2 year(s) ago
Astrocyte interleukin-3 preps microgliaBrain β-amyloid (Aβ) deposition is a biomarker for Alzheimer’s disease (AD) and other dementias, in which Aβ amounts correlate with disease burden. McAlpine et al. reveal that astrocyte expression or administration of interleukin (IL)-3 in the context of aggregated Aβ endows microglia with enhanced capability to cluster and clear Aβ oligomers.Full-Text…
Source: www.cell.comCategories: Allergy-Immunology, Latest HeadlinesTweet-
November @TrendsImmuno #astrocyte #IL3, #lymphatics, cytosolic bacteria, #cGAS, #mTOR #gasdermin, #Bcell memory, #ADAR1 #antiviral, #SARSCoV2, #Checkpoint #immunity, #cancer-immunity #metabolism, #Tcell activation, #IFN #mucosa, #RORgt #IL17, #inflammation https://t.co/uBGvZr0m7v https://t.co/ZbeQayxoQQ
-
-
Mashup Score: 4
Dr. Peter Crino’s research program focuses on defining developmental brain disorders, specifically those associated with aberrant mammalian target of rapamycin (mTOR) signaling. Recently, Dr. Crino’s lab identified new mutations in mTOR pathway genes (MPGs) that are associated with a clinical syndrome characterized by megalencephaly (a condition characterized by overdeveloped
Source: www.ninds.nih.govCategories: Latest Headlines, NeurologyTweet-
Congratulations to AES member + volunteer, @PeterCrino, who received the Javits Award from @NINDSnews. Dr. Crino's lab recently ID'd new mutations in #mTOR pathway genes associated w/ a syndrome marked by megalencephaly, #autism, severe #epilepsy + more. https://t.co/IxrhD2dNvq https://t.co/8fdZZAkiT6
-
-
Mashup Score: 0Neoadjuvant Everolimus for Adult Giant Mesenteric Cystic Lymphangioma with mTOR Pathway Activation - 3 year(s) ago
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
Source: The OncologistCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Neoadjuvant Everolimus for Adult Giant Mesenteric Cystic Lymphangioma with mTOR Pathway Activation #CysticLymphangioma #mTOR #PI3KCA #Everolimus https://t.co/Vcyag2Q9Oy https://t.co/HWoYik5VAc
-
💊@SBLabUCSF identified a new class of drugs that can be used to treat aggressive, treatment resistant #BreastCancers 🔬https://t.co/sAuqJOGDdN #OpenAccess #mTOR